Business
Medicenna Announces Overnight Marketed Offering of Common Shares
Medicenna Announces Overnight Marketed Offering of Common Shares Canada NewsWire ...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Announces Overnight Marketed Offering of Common Shares\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, March 3, 2020\n\n\n\n/NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./\n TORONTO and HOUSTON, March 3, 2020 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSX: MDNA), a clinical stage immuno-oncology company, announced today that it has filed and been receipted for a preliminary short form prospectus (the \"Preliminary Prospectus\") with securities regulatory authorities in the provinces of Ontario, British Columbia and Alberta pursuant to National Instrument 44-101 Short Form Prospectus Distributions, in connection with a proposed marketed offering (the \"Offering\") of common shares of the Company (the \"Offered Shares\"). The Offering is being led by Bloom Burton Securities Inc. (the \"Lead Agent\") on behalf of a syndicate including Mackie Research Capital Corp. and Haywood Securities Inc.\nThe size of the Offering and the price of each Offered Share, will be determined by negotiation between the Company and the Lead Agent in the context of the market with final terms to be determined at the time of pricing. The Preliminary Prospectus is subject to completion and amendment.\nThe net proceeds of the Offering will be used to fund pre-clinical development of the Company's lead IL-2 agonist drug candidate MDNA19, the manufacturing of MDNA19 and general corporate and working capital purposes. Further details are disclosed in the Preliminary Prospectus, available at www.sedar.com.\nThe Offering is subject to a number of customary conditions, including, without limitation, receipt of all regulatory and stock exchange approvals.  \nThe Offered Shares have not been registered under the United States Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold in the United States absent registration or an exemption from such registration requirements.  This ...